(Morning News) Pfizer in the United States Pharmaceutical Factory said that after the treatment of crown disease oral medication PAXLOVID, patients with crown diseases were recurred in the face of the symptoms of the coronary disease.However, according to the guidelines of the U.S. Regulatory Administration, restrictions on people can only take it for five consecutive days.
Peng Pao reported that Pharaoh President Albervan said in an interview: "The function of Paxlovid is to reduce the load of the virus, and then your body will take over this task."
However, some patients with coronary disease cannot eliminate the virus after completing the oral medication treatment of the coronary disease due to unknown reasons.Pfizer executives believe that this situation is quite rare and has nothing to do with crown oral medicine.
Aberle said that in the case of the coronary virus load recovered horizontally, "you should use the second course of treatment, just like the principle of antibiotics."
relatedHow to prescribe medicines with a virus -load level, and the Corolutic patients who have risen crown diseases have not responded immediately.FDA approved the emergency use authorization of PaxLovid at the end of last year, but the oral drug has not been fully approved.The official current prescribed guidelines show that the oral medication has not been authorized to allow people to take it for more than five consecutive days.
A scientist at the National Institute of Allergies and Infectious Diseases pointed out that understanding why some coronary patients will rebound in the virus level after a five -day treatment.The American Centers for Disease Control and Prevention (CDC) is providing relevant data to assist in studying this phenomenon.
